Cepheid

Cepheid is a molecular diagnostics company specializing in rapid, point-of-care testing systems and molecular assays. The company's flagship GeneXpert® System is a fully scalable platform offering a broad menu of diagnostic tests across infectious disease, respiratory health, gastrointestinal disorders, and other clinical areas. Their platform serves settings from core laboratories to near-patient and point-of-care applications, enabling fast turnaround results for improved clinical decision-making. Cepheid's test portfolio includes PCR-based assays for tuberculosis, respiratory infections, gastrointestinal pathogens, and healthcare-associated infections. The company markets solutions to laboratory professionals, healthcare providers, and health system administrators. Cepheid operates a Global Access Program focused on expanding diagnostic access in underserved and resource-limited regions, including support for cervical cancer screening and TB elimination initiatives. Products are designed for workflow connectivity and integration within healthcare settings. The company emphasizes rapid, accurate diagnostic results to support effective patient management and antimicrobial stewardship. Manufacturing and regulatory compliance are implied through FDA and international certifications typical of molecular diagnostic systems.